Mastiha supplementation led to a significant reduction in circulating alanine aminotransferase (ALT) activity, improvement in hepatic steatosis and collagen content, and a reduction in NAFLD activity score. The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.